Cited by 33Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesBehavioral and Psychological Studies

Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder

Ramos-Quiroga, J. Antoni, Casas, Miguel·2011·CNS Drugs

Abstract

Remission should be the goal of attention-deficit hyperactivity disorder (ADHD) treatment. However, there is no universally accepted definition of remission in ADHD, although clinical studies use a number of criteria. This article examines current research into the concept of remission in ADHD by reviewing the literature for definition and achievement of remission in children and adults with ADHD. Results demonstrate that the concept of remission in ADHD has been proposed by several study groups, using thresholds of validated rating scales to indicate syndromic, symptomatic and functional remission. Several studies have demonstrated the achievement of remission in ADHD children utilizing methylphenidate delivered by an osmotic, controlled-release formulation (OROS®) and atomoxetine. However, none has defined a time period over which these criteria must be met for an individual with ADHD to be considered 'in remission'. Standardized remission criteria in ADHD will provide a tool for assessing the effectiveness of treatments for ADHD, and raise treatment standards.

Integrity signals

Registry

Crossref · 10.2165/11538450-000000000-00000

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ramos-Quiroga, J. A., & Casas, M.
Affiliations
Universitat Autònoma de Barcelona (ES)
Venue
CNS Drugs
Published
2011-01
Volume
25
Issue
1
Pages
17-36
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2048875335
Cited by
33
References
17
Citations by year
2025: 1 · 2024: 1 · 2019: 1 · 2018: 2 · 2015: 4 · 2014: 7 · 2013: 10 · 2012: 7
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
attention deficit hyperactivity disorder, remission, remission criteria, pharmacotherapy, methylphenidate, atomoxetine, OROS methylphenidate, children, adults, rating scales, treatment effectiveness
MeSH terms
Adult, Attention Deficit Disorder with Hyperactivity, Child, Humans, Remission Induction, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review